International Institute of Cancer Immunology, Inc.

Osaka University

Nitto-denko Corporation

Chugai Seiyaku Kabushiki Kaisha

Dainippon Sumitomo Pharma Co., Ltd.

Haruo Sugiyama

Otsuka Pharmaceutical Company, Limited

Nippon Light Metal Company, Ltd.

Knc Laboratories Co., Ltd.

International Institute of Immunology, Inc.

International Institute of Cancer Immunology, Ind.

Sugiyama, Haruo

Mayumi, Tadanori

Yusuke Oji

Yoshihiro Oka

Mitsuhiko Hori

Daisuke Asari

Katsuyuki Okubo

Arimichi Okazaki

Yoshiki Maeda

Takuya Shishido

Hideo Takasu

Fumihiro Fujiki

Shinji Sogo

Masashi Gotoh

Yoshihiro Goto

Naoki Hosen

Hideki Suzuki

Kyohei Matsushita

Toshiya Anami

Yoshito Oki

Junichi Takagi

Tomohiro Sasaki

Atsushi Kumanogoh

Fumio Samizo

Ryuki Kitamoto

Hideaki Tanaka

Kiyonori Katsuragi

Masahiro Neya

Yoshiyuki Ohsugi

Masayoshi Sato

Yasukazu Ohmoto

Wenjing Li

Toshiki Yoshimine

Naoto Kusunose

Masashi Nakatsuka

Shinya Kohno

Husako Iwata

Hiroshi Kubo

Akihiro Tsuboi

Naoya Hashimoto

Tadanori Mayumi

The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and/or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1killer peptide and/or WT1helper peptide. In another aspect, provided are a method of inducing WT1 peptide-specific CTLs, a method of inducing WT1-specific helper T cells, and a method of inducing dendritic cells presenting a WT1 peptide.

Composition for preventing or treating benign tumor

The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1*0101 molecule, an HLA-DRB1*0401 molecule, an HLA-DRB1*0403 molecule, an HLA-DRB1*0406 molecule, an HLA-DRB1*0803 molecule, an HLA-DRB1*0901 molecule, an HLA-DRB1*1101 molecule, an HLA-DRB3*0202 molecule, an HLA-DRB4*0101 molecule, an HLA-DPB1*0201 molecule or an HLA-DPB1*0301 molecule, and the like.

Method for activating helper T cell

The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.

Cancer antigen helper peptide

A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.

Cancer vaccine composition

Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.

Method for activation of helper t cell and composition for use in the method

The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.

Immunotherapy for angiogenic disease

The present invention pertains to polynucleotides that encode CDR3 in TCR-[alpha] and TCR-[beta] chain genes of CD4helper T-cells that are specific to WT1 helper peptides having an amino acid sequence represented by SEQ ID NO: 123. The present invention further pertains to the peptides encoded by said polynucleotides. The present invention further pertains to CD4T cells into which TCR genes that contain said polynucleotides have been introduced, the induction of WT1-specific cytotoxic T-lymphocytes (CTLs) using the CD4T-cells, the treatment of cancer, etc.

Antigen-specific helper T-cell receptor genes

The present invention provides a WT1-derived HLA-DRB1*0405-binding antigen peptide, a polynucleotide encoding said peptide, a helper T cell inducer comprising said peptide or polynucleotide, and the like. It is related to a partial peptide consisting of 10-25 contiguous amino acids in the amino acid sequence of human WT1 shown in SEQ ID NO: 1, which binds to HLA-DRB1*0405 and induces helper T cells, a polynucleotide encoding said peptide, or a helper T cell inducer comprising said peptide or polynucleotide.

HLA-DR-binding antigen peptide derived from WT1

Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin &#x3b2;.

Antibody

Provided is a method for increasing the proportion of memory T cells in a T cell population, said method comprising a step of adding a modulator for the retinoid metabolic pathway and/or a modulator for the retinoic acid signaling system to the T cell population.

Method for modifying T cell population

Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious disease; a cancer immunotherapeutic adjuvant; an immunopotentiator; and a method for preparing a T cell population wherein the ratio of memory T cells is increased, said method comprising using the compound of formula (I).

Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.

Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them

Growing community of inventors

Minoo, Japan

Haruo Sugiyama